Immune suppression proposed as way to slow Parkinson’s progression
Suppressing the immune system to reduce brain inflammation, a known contributor to Parkinson’s disease progression, may offer a promising…
Articles by Michela Luciano, PhD
AAN 2025: Crexont improves sleep quality in Parkinson’s patients
Crexont, an extended-release oral formulation of carbidopa and levodopa, significantly improved sleep quality in people with Parkinson’s disease.
New targeted approach protects neurons from degeneration: Study
U.S. researchers have identified a novel way to block a protein known as DLK, or dual leucine-zipper kinase, that may…
Pretzel advances mitochondrial therapy with PX578 Phase 1 trial
Pretzel Therapeutics has launched a Phase 1 clinical trial to study PX578, a therapy designed to boost the function…
Benefits seen with solengepras as solo Parkinson’s therapy: Trial
When used as a solo therapy, solengepras (CVN424) — an oral treatment being developed by Cerevance — was seen…
Common medications may delay Parkinson’s disease onset: Study
Medications commonly used to treat conditions such as high blood pressure, high cholesterol, and pain may delay Parkinson’s disease…
PET radiotracer captures inflammation in human brain
A new positron emission tomography (PET) radiotracer can accurately visualize inflammation within the healthy human brain, a first-in-human study found.
Potential oral therapy for apathy to enter clinical trial in patients
Irlab Therapeutics is moving its oral candidate, IRL757, into a Phase 1b clinical study to assess its safety and…
MJFF assembling experts toward research on new Parkinson’s targets
The Michael J. Fox Foundation (MJFF) has brought together top experts from around the world to speed up research…